Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM5OGK0)

Drug Name
Epalrestat Drug Info
Synonyms
epalrestat; 82159-09-9; Kinedak; Epalrestatum; Ono 2235; Ono-2235; Epalrestat [INN]; Epalrestatum [Latin]; ONO-2; 2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid; ONO 2; UNII-424DV0807X; C15H13NO3S2; CHEMBL56337; 5-((1Z,2E)-2-Methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; CHEBI:31539; 5-((Z,E)-beta-Methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; 424DV0807X; Epalrestatum; Aldorin (TN); Kinedak (TN); Epalrestat (JAN/INN); {5-[(E)-2-Methyl-3-phenyl-prop-2-en-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid; 3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine; Ono 2
Therapeutic ClassHypoglycemic Agents
Cross-matching ID
PubChem CID
1549120
ChEBI ID
CHEMBL56337
CAS Number
CAS 82159-09-9
TTD Drug ID
D03KOZ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Primary bile acid biosynthesis 1.73 3.45e-1 15/17 (88.24%) AMACR;CYP7A1;CH25H;...
Antigen processing and presentation 1.68 3.24e-1 60/78 (76.92%) HSP90AA1;HSP90AB1;CD74;...
Phenylalanine metabolism 1.67 2.81e-1 14/17 (82.35%) MAOB;HPD;GLYAT;...
Collecting duct acid secretion 1.61 3.37e-1 22/27 (81.48%) SLC4A1;ATP6V1C1;CA2;...
mRNA surveillance pathway 1.60 3.07e-1 71/98 (72.45%) PPP2CB;PNN;EIF4A3;...
Long-term depression 1.57 3.00e-1 55/60 (91.67%) PPP2CB;KRAS;GNAS;...
D-Glutamine and D-glutamate metabolism 1.53 3.49e-1 5/5 (100%) GLUD1;GLUD2;GLS
Spliceosome 1.53 3.17e-1 101/150 (67.33%) PUF60;DDX42;HNRNPC;...
Fc epsilon RI signaling pathway 1.53 2.83e-1 57/68 (83.82%) KRAS;ALOX5AP;FCER1G;...
Phosphonate and phosphinate metabolism 1.49 3.51e-1 5/6 (83.33%) CHPT1;CEPT1;PCYT2
Sphingolipid signaling pathway 1.49 3.20e-1 106/119 (89.08%) PPP2CB;KRAS;ROCK2;...
Oocyte meiosis 1.49 3.03e-1 90/129 (69.77%) PPP2CB;CDC20;PPP3CA;...
Drug metabolism 1.49 2.83e-1 78/151 (51.66%) MAOB;GSTA1;CYP2A6;...
IL-17 signaling pathway 1.48 2.72e-1 84/94 (89.36%) S100A8;S100A9;S100A7;...
Phagosome 1.45 3.24e-1 118/152 (77.63%) THBS2;ATP6AP1;HLA-DRA;...
Protein processing in endoplasmic reticulum 1.45 3.27e-1 127/171 (74.27%) RAD23B;MAN1C1;BAG2;...
Hippo signaling pathway 1.44 3.17e-1 120/186 (64.52%) PPP2CB;PAK1;FZD7;...
Steroid hormone biosynthesis 1.43 3.15e-1 43/61 (70.49%) HSD11B1;AKR1C3;HSD17B6;...
Complement and coagulation cascades 1.41 3.72e-1 76/85 (89.41%) CFB;PLAUR;C5AR1;...
Natural killer cell mediated cytotoxicity 1.40 3.57e-1 99/131 (75.57%) PAK1;TNFSF10;PRF1;...
Synaptic vesicle cycle 1.40 3.57e-1 63/78 (80.77%) SYT1;SLC1A1;SNAP25;...
Dopaminergic synapse 1.39 3.51e-1 115/132 (87.12%) PPP2CB;MAOB;GNAS;...
Staphylococcus aureus infection 1.39 3.46e-1 72/95 (75.79%) KRT18;CFB;KRT13;...
Arginine biosynthesis 1.39 3.39e-1 17/22 (77.27%) GLUL;GLUD1;ARG2;...
Chemical carcinogenesis 1.37 3.73e-1 186/281 (66.19%) HSP90AA1;IKBKE;HSP90AB1;...
Non-homologous end-joining 1.37 3.73e-1 11/13 (84.62%) MRE11;DNTT;NHEJ1;...
Carbohydrate digestion and absorption 1.36 3.79e-1 37/47 (78.72%) SLC37A4;HK1;SLC2A2;...
Glycolysis / Gluconeogenesis 1.35 3.76e-1 56/67 (83.58%) ALDH2;ENO1;PGAM1;...
Cellular senescence 1.34 3.80e-1 139/156 (89.1%) GADD45A;CHEK1;KRAS;...
Pantothenate and CoA biosynthesis 1.34 3.70e-1 14/21 (66.67%) ALDH2;BCAT1;DPYS;...
Intestinal immune network for IgA production -1.19 6.81e-1 38/48 (79.17%) TGFB1;TNFRSF13B;HLA-DQB1;...
Parkinson disease -1.20 6.83e-1 176/249 (70.68%) NDUFB8;TH;ATP5MC2;...
Inflammatory mediator regulation of TRP channels -1.23 5.94e-1 82/98 (83.67%) ALOX12;PLCB1;ADCY3;...
Yersinia infection -1.24 5.87e-1 120/137 (87.59%) CHUK;CXCL8;ELMO2;...
Toxoplasmosis -1.24 6.04e-1 103/112 (91.96%) LAMC1;LAMC2;HLA-DQB1;...
Glioma -1.25 5.99e-1 67/75 (89.33%) PLCG1;CAMK1;PRKCA;...
Chemokine signaling pathway -1.25 6.22e-1 163/192 (84.9%) CCL8;CHUK;CXCL8;...
Phosphatidylinositol signaling system -1.25 6.32e-1 82/97 (84.54%) PI4KB;PLCB1;PLCG1;...
Glycosaminoglycan degradation -1.26 6.46e-1 19/19 (100%) HYAL2;NAGLU;HGSNAT;...
Notch signaling pathway -1.26 6.61e-1 49/59 (83.05%) JAG2;NCOR2;NOTCH3;...
Diabetic cardiomyopathy -1.26 6.71e-1 162/203 (79.8%) GSK3B;CYBA;NDUFB8;...
Huntington disease -1.29 5.89e-1 233/306 (76.14%) NDUFB8;ATP5MC2;POLR2B;...
Focal adhesion -1.31 5.45e-1 180/201 (89.55%) CAV1;LAMC1;COL6A2;...
Ether lipid metabolism -1.31 5.69e-1 32/49 (65.31%) PLD3;PLA2G2D;PLPP1;...
Protein digestion and absorption -1.31 5.98e-1 78/103 (75.73%) COL4A1;COL4A3;CELA2A;...
Pertussis -1.31 6.20e-1 64/76 (84.21%) CXCL8;CALML3;JUN;...
Ribosome -1.32 6.20e-1 113/158 (71.52%) RPS19;RPLP2;RPLP1;...
Bacterial invasion of epithelial cells -1.33 6.49e-1 59/77 (76.62%) ELMO2;SHC1;PIK3R1;...
Small cell lung cancer -1.33 6.75e-1 90/92 (97.83%) RXRA;CCNE1;FN1;...
Oxidative phosphorylation -1.34 6.78e-1 93/133 (69.92%) ATP6V0E1;NDUFB8;ATP5MC2;...
Viral protein interaction with cytokine and cytokine re... -1.36 6.63e-1 84/100 (84%) LTA;IL10RB;CCL8;...
Breast cancer -1.46 3.71e-1 119/147 (80.95%) FZD1;WNT7A;KIT;...
Thermogenesis -1.47 3.96e-1 173/232 (74.57%) ATP5F1D;NPPA;COA7;...
Th1 and Th2 cell differentiation -1.48 4.26e-1 80/92 (86.96%) RUNX3;TBX21;RBPJ;...
Terpenoid backbone biosynthesis -1.50 4.25e-1 18/22 (81.82%) PCYOX1;DHDDS;MVK;...
ECM-receptor interaction -1.59 2.26e-1 80/88 (90.91%) FN1;COL9A1;ITGA10;...
Pancreatic secretion -1.66 1.32e-1 87/102 (85.29%) SLC4A2;CLCA4;PLCB1;...
Non-alcoholic fatty liver disease -1.66 1.64e-1 126/155 (81.29%) NDUFB11;COX7A1;FAS;...
Steroid biosynthesis -1.72 1.50e-1 19/20 (95%) LSS;SQLE;EBP;...
Mineral absorption -1.79 1.64e-1 48/60 (80%) MT1G;TRPV6;HEPH;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 10uM 24H
SH-4 CVCL_1692 Homo sapiens 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 10uM 24H